Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug ...

It has sold copies of its dataset to around 30, including Genentech for $65 million in 2015, and more recently, to GlaxoSmithKline, earning $300 million. But to collect enough DNA, it needed to ...

It was followed by rival GSK, which tumbled 5.7 per cent, or 76.5p, to 1264p. The slump in drugmakers’ stocks came after the US president said overnight that the US would soon introduce a ...

GSK recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and the EMA's acceptance of an application for Nucala's expanded use. Despite these ...

GSK is funding public health organizations working to address US adult immunization gaps and increase community vaccine education, outreach and access These grants are part of GSK’s COiMMUNITY ...

ET NOW Panellist Kunal Bothra has recommended three stocks – Asian Paints, GlaxoSmithKline Pharmaceuticals, and Indus Towers Ltd. Asian Paints Share Price Target 2025: Rs 2500; Stop Loss – Rs ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing respiratory syncytial virus (RSV) vaccines, according to a filing made in Delaware ...

Amid the current market turmoil, it is worth remembering that the pharmaceutical industry must continue its normal business of ensuring that it has products to sell in 10 years, with GSK (GSK) signing ...

AstraZeneca dropped 6.80% GlaxoSmithKline (GSK) dropped by 5.48% Novo Nordisk - which produces weight-loss drugs Ozempic and Wegovy - has fallen 6.93% The trade in goods between the two economic ...

Mumbai: GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Upendra Singh, Commercial Head - General Medicines, effective from the close of business hours of 18th April 2025.

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.

Big pharmaceutical companies have been making deals for technologies that could help them get their molecules through this protective membrane and now GSK is joining in, striking up an alliance ...